Full Text View
Tabular View
Study Results
Related Studies
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
This study has been completed.
First Received: May 7, 2004   Last Updated: November 16, 2009   History of Changes
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00082433
  Purpose

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.


Condition Intervention Phase
Cancer
Breast Cancer
 Drug: Ixabepilone + Capecitabine
Drug: Capecitabine
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: Capecitabine Ixabepilone
U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: from date of randomization until death ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression ] [ Designated as safety issue: No ]
  • Response Rate (RR) [ Time Frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression ] [ Designated as safety issue: No ]
  • Duration of Response [ Time Frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression ] [ Designated as safety issue: No ]
  • Time to Response [ Time Frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression ] [ Designated as safety issue: No ]
  • Treatment-Related Safety Summary [ Time Frame: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible. ] [ Designated as safety issue: Yes ]
  • Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) [ Time Frame: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment ] [ Designated as safety issue: No ]

Enrollment: 1221
Study Start Date: November 2003
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Experimental Drug: Ixabepilone + Capecitabine
Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
B: Active Comparator Drug: Capecitabine
Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria
  • Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).
  • Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.
  • Patients may not have any history of brain and/or leptomeningeal metastases.
  • Patients may not have Grade 2 or worse neuropathy at the time of study entry.
  • Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00082433

  Hide Study Locations
Locations
United States, Arizona
Local Institution
Tuscon, Arizona, United States
United States, California
Local Institution
Beverly Hills, California, United States
Local Institution
Corona, California, United States
United States, Connecticut
Local Institution
Hartford, Connecticut, United States
United States, Florida
Local Institution
Plantation, Florida, United States
United States, Idaho
Local Institution
Boise, Idaho, United States
United States, Illinois
Local Institution
Evanston, Illinois, United States
United States, Iowa
Local Institution
Iowa City, Iowa, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Louisiana
Local Institution
Baton Rouge, Louisiana, United States
United States, Maryland
Local Institution
Bethesda, Maryland, United States
United States, Massachusetts
Local Institution
Boston, Massachusetts, United States
United States, Mississippi
Local Institution
Jackson, Mississippi, United States
United States, Missouri
Local Institution
Columbia, Missouri, United States
United States, New Jersey
Local Institution
Voorhees, New Jersey, United States
United States, New Mexico
Local Institution
Albuquerque, New Mexico, United States
United States, New York
Local Institution
New York, New York, United States
Local Institution
Bronx, New York, United States
Local Institution
Mineola, New York, United States
Local Institution
Latham, New York, United States
United States, North Carolina
Local Institution
Hickory, North Carolina, United States
Local Institution
Durham, North Carolina, United States
Local Institution
Goldsboro, North Carolina, United States
Local Institution
Kinston, North Carolina, United States
United States, Ohio
Local Institution
Columbus, Ohio, United States
Local Institution
Canton, Ohio, United States
United States, Pennsylvania
Local Institution
Langhorne, Pennsylvania, United States
United States, Tennessee
Local Institution
Knoxville, Tennessee, United States
Local Institution
Memphis, Tennessee, United States
Local Institution
Knoxville, Tennessee, United States
United States, Texas
Local Institution
Dallas, Texas, United States
United States, Virginia
Local Institution
Richmond, Virginia, United States
Local Institution
Norfolk, Virginia, United States
Local Institution
Charlottesville, Virginia, United States
United States, Wisconsin
Local Institution
Marshfield, Wisconsin, United States
Argentina
Local Institution
Buenos Aires, Argentina
Local Institution
Buenos Aires, Argentina
Local Institution
Buenos Aires, Argentina
Local Institution
Mendoza, Argentina
Local Institution
Salta, Argentina
Local Institution
Santa Fe, Argentina
Argentina, Buenos Aires
Local Institution
Bahia Blanca, Buenos Aires, Argentina
Local Institution
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution
Avelianeda, Buenos Aires, Argentina
Local Institution
Escobar, Buenos Aires, Argentina
Local Institution
Bahia Blanca, Buenos Aires, Argentina
Argentina, Chaco
Local Institution
Resistencia, Chaco, Argentina
Argentina, Cordoba
Local Institution
Barrio Alto Verde, Cordoba, Argentina
Argentina, Tucuman
Local Institution
San Miguel de Tucuman, Tucuman, Argentina
Australia, New South Wales
Local Institution
Sydney, New South Wales, Australia
Local Institution
Westmead, New South Wales, Australia
Australia, Queensland
Local Institution
South Brisbane, Queensland, Australia
Local Institution
Herston, Queensland, Australia
Local Institution
Toowoomba, Queensland, Australia
Local Institution
Brisbane, Queensland, Australia
Australia, South Australia
Local Institution
Woodville, South Australia, Australia
Local Institution
Adelaide, South Australia, Australia
Australia, Victoria
Local Institution
Parkville, Victoria, Australia
Local Institution
East Melbourne, Victoria, Australia
Australia, Western Australia
Local Institution
Perth, Western Australia, Australia
Austria
Local Institution
Voecklabruck, Austria
Local Institution
Wien, Austria
Local Institution
Graz, Austria
Local Institution
Wien, Austria
Belgium
Local Institution
Charleroi, Belgium
Local Institution
Bruxelles, Belgium
Local Institution
Wilrijk, Belgium
Local Institution
Kortrijk, Belgium
Local Institution
Hasselt, Belgium
Local Institution
Gent, Belgium
Brazil
Local Institution
Rio de Janeiro, Brazil
Brazil, Rio Grande Do Sul
Local Institution
Centro-Porto Alegre, Rio Grande Do Sul, Brazil
Brazil, Sao Paulo
Local Institution
Higienopolis, Sao Paulo, Brazil
Local Institution
Bela Vista, Sao Paulo, Brazil
Brazil, Sp
Local Institution
Sao Paulo, Sp, Brazil
Canada, Ontario
Local Institution
Thunder Bay, Ontario, Canada
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
Chile, Metropolitana
Local Institution
Santiago, Metropolitana, Chile
Local Institution
Santiago, Metropolitana, Chile
China
Local Institution
Beijing, China
Local Institution
Beijing, China
Local Institution
Beijing, China
Local Institution
Beijing, China
Local Institution
Shanghai, China
China, Guangdong
Local Institution
Guangzhou, Guangdong, China
China, Jiangsu
Local Institution
Nanjing, Jiangsu, China
Local Institution
Nanjing, Jiangsu, China
China, Liaoning
Local Institution
Dalian, Liaoning, China
Local Institution
Dilian, Liaoning, China
China, Shan3xi
Local Institution
Xi'An, Shan3xi, China
China, Shandong
Local Institution
Jinan, Shandong, China
China, Zhejiang
Local Institution
Hangzhou, Zhejiang, China
Local Institution
Hangzhou, Zhejiang, China
Croatia
Local Institution
Split, Croatia
Local Institution
Zagreb, Croatia
Local Institution
Zagreb, Croatia
Czech Republic
Local Institution
Brno, Czech Republic
Local Institution
Prague, Czech Republic
Local Institution
Prague, Czech Republic
Local Institution
Hradec Kralove, Czech Republic
Local Institution
Prague 5, Czech Republic
Denmark
Local Institution
Aalborg, Denmark
Local Institution
Kobenhavn O, Denmark
Local Institution
Herlev, Denmark
France
Local Institution
Paris Cedex 13, France
Local Institution
Villejuif Cedex, France
Local Institution
Le Mans, France
Local Institution
Caen, France
Local Institution
Pierre Benite, France
Local Institution
Bordeaux, France
Local Institution
Tours Cedex, France
Local Institution
Metz, France
Local Institution
Colmar, France
Local Institution
Reims, France
Local Institution
Saint Gregoire, France
Local Institution
Saint Herblain, France
Local Institution
Clermont-Ferrand, France
Local Institution
Angers, France
Local Institution
Saint Brieuc, France
Germany
Local Institution
Munchen, Germany
Local Institution
Berlin, Germany
Local Institution
Essen, Germany
Local Institution
Tubingen, Germany
Local Institution
Wiesbaden, Germany
Local Institution
Erlangen, Germany
Local Institution
Hannover, Germany
Local Institution
Kiel, Germany
Local Institution
Ulm, Germany
Local Institution
Marburg, Germany
Local Institution
Karlsruhe, Germany
Local Institution
Rehling, Germany
Local Institution
Saarbrucken, Germany
Local Institution
Berlin, Germany
Greece
Local Institution
Patras, Greece
Local Institution
Crete, Greece
Local Institution
Athens, Greece
Local Institution
Thessaloniki, Greece
Local Institution
Thessaloniki, Greece
Ireland
Local Institution
Galway, Ireland
Local Institution
Dublin 9, Ireland
Local Institution
Dublin, Ireland
Local Institution
Dublin 8, Ireland
Local Institution
Dublin, Ireland
Local Institution
Cork, Ireland
Ireland, Cork
Local Institution
Wilton, Cork, Ireland
Israel
Local Institution
Tel Aviv, Israel
Local Institution
Haifa, Israel
Local Institution
Ramat-Gan, Israel
Local Institution
Jerusalem, Israel
Local Institution
Haifa, Israel
Italy
Local Institution
Roma, Italy
Local Institution
Modena, Italy
Local Institution
Firenze, Italy
Local Institution
Genova, Italy
Local Institution
Potenza, Italy
Local Institution
Roma, Italy
Local Institution
Perugia, Italy
Local Institution
Milano, Italy
Local Institution
Bari, Italy
Local Institution
Roma, Italy
Local Institution
San Giovanni Rotondo, Italy
Local Institution
Torino, Italy
Local Institution
Sora, Italy
Italy, Milan
Local Institution
Rozzano, Milan, Italy
Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Incheon, Korea, Republic of
Local Institution
Gyeonggi-Do, Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Netherlands
Local Institution
Enschede, Netherlands
Local Institution
Den Haag, Netherlands
Local Institution
Zwolle, Netherlands
Local Institution
Arnhem, Netherlands
Portugal
Local Institution
Coimbra, Portugal
Local Institution
Coimbra, Portugal
Local Institution
Lisboa, Portugal
Russian Federation
Local Institution
St. Petersburg, Russian Federation
Local Institution
Moscow, Russian Federation
Local Institution
Moscow, Russian Federation
Local Institution
Kazan, Russian Federation
Local Institution
Kazan, Russian Federation
Singapore
Local Institution
Singapore, Singapore
Local Institution
Singapore, Singapore
South Africa, Eastern Cape
Local Institution
Port Elizabeth, Eastern Cape, South Africa
South Africa, Gauteng
Local Institution
Johannesburg, Gauteng, South Africa
Local Institution
Johannesburg, Gauteng, South Africa
Local Institution
Pretoria, Gauteng, South Africa
Local Institution
Pretoria, Gauteng, South Africa
South Africa, Western Cape
Local Institution
Panorama, Western Cape, South Africa
Spain
Local Institution
Hospitalet de Llobregat, Spain
Local Institution
Tenerife, Spain
Local Institution
Madrid, Spain
Local Institution
Elche (Alicante), Spain
Local Institution
Pontevedra, Spain
Local Institution
Valencia, Spain
Local Institution
Barcelona, Spain
Local Institution
Jaen, Spain
Local Institution
Salamanca, Spain
Local Institution
Madrid, Spain
Local Institution
Cordoba, Spain
Local Institution
Sevilla, Spain
Local Institution
Zaragoza, Spain
Local Institution
Valencia, Spain
Local Institution
Madrid, Spain
Local Institution
Cadiz, Spain
Local Institution
Sevilla, Spain
Local Institution
Reus, Spain
Spain, Barcelona
Local Institution
Terassa, Barcelona, Spain
Switzerland
Local Institution
Bern, Switzerland
Local Institution
Zurich, Switzerland
Local Institution
Thun, Switzerland
Taiwan
Local Institution
Taipei, Taiwan
Local Institution
Taipei, Taiwan
Local Institution
Taipei, Taiwan
Turkey
Local Institution
Izmir, Turkey
Local Institution
Istanbul, Turkey
Local Institution
Istanbul, Turkey
Local Institution
Izmir, Turkey
Local Institution
Ankara, Turkey
United Kingdom, Armagh
Local Institution
Belfast, Armagh, United Kingdom
United Kingdom, Central
Local Institution
Glasgow, Central, United Kingdom
United Kingdom, Greater London
Local Institution
London, Greater London, United Kingdom
Local Institution
London, Greater London, United Kingdom
Local Institution
London, Greater London, United Kingdom
United Kingdom, Shropshire
Local Institution
Shrewsbury, Shropshire, United Kingdom
United Kingdom, West Midlands
Local Institution
Birmingham, West Midlands, United Kingdom
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site
Phrma website - CSR synopsis  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Bristol-Myers Squibb ( Study Director )
Study ID Numbers: CA163-048
Study First Received: May 7, 2004
Results First Received: May 1, 2009
Last Updated: November 16, 2009
ClinicalTrials.gov Identifier: NCT00082433     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Antimetabolites
Capecitabine
Antimetabolites, Antineoplastic
Immunologic Factors
Skin Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Epothilones
Mitosis Modulators
Physiological Effects of Drugs
 Breast Neoplasms
Antimitotic Agents
Immunosuppressive Agents
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Therapeutic Uses
Fluorouracil
Tubulin Modulators
Breast Diseases

ClinicalTrials.gov processed this record on November 27, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services